RXRX (Recursion Pharmaceuticals) Institutional Ownership: 72.25% (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RXRX Recursion Pharmaceuticals Inc RXRX
79 GF Score
Price $2.98
GF Value $4.06
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Institutional Ownership?

Recursion Pharmaceuticals RXRX -1.97% 79 Institutional Ownership is 72.25% as of Jul. 31, 2026. GuruFocus rates RXRX with a GF Score™ of 79/100 and a GF Value™ of $4.06 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Recursion Pharmaceuticals's institutional ownership is 72.25%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Recursion Pharmaceuticals's Insider Ownership is 3.10%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Recursion Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 94.34%.

Recursion Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Institutional Ownership Chart

Recursion Pharmaceuticals Historical Data

The historical data trend for Recursion Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 45.46 43.48 44.20 47.52 47.38 48.23 50.02 49.56 49.49 53.53
RXRX
79GF Score
Recursion Pharmaceuticals Inc RXRX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 72.25% mean?
Recursion Pharmaceuticals (RXRX) has a Institutional Ownership of 72.25% as of Jul. 31, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Institutional Ownership too high?
Recursion Pharmaceuticals' current Institutional Ownership is 72.25%. Overall, Recursion Pharmaceuticals has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Institutional Ownership compare to INVA and TSHA?
Recursion Pharmaceuticals' Institutional Ownership of 72.25% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Institutional Ownership is 72.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.06, compared to a current price of $2.98 — trading 26.6% below its estimated fair value. The current Institutional Ownership is 72.25%. Recursion Pharmaceuticals' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Institutional Ownership is 72.25% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $2.98 is trading 26.6% below its estimated GF Value™ of $4.06. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RXRX:

  • Institutional Ownership: 72.25%
  • GF Value™: $4.06 vs. price of $2.98 (26.6% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
79GF Score

Get the complete analysis for RXRX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price
$4.06
GF Value